AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine

(14min)

Summary

  • AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline.
  • Management expects a return to "robust" mid-single-digit revenue growth in 2025, which suggests full-year 2025 guidance will be largely in line with the analyst consensus.
  • AbbVie is not giving up on emraclidine based on trial conduct and drug exposure observations in the failed phase trial in schizophrenia patients in late 2024.
  • If the company updates its long-term guidance, I expect to see upside revisions for Rinvoq and Skyrizi and a potential downside revision for the aesthetics business.
  • I do much more than just articles at Growth Stock Forum: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Close up image of paper clipboard with text FOURTH QUARTER.

mohd izzuan

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net sales remains the key moving

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up to Growth Stock Forum.

This article was written by

9.21K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABBV

Related Stocks

SymbolLast Price% Chg
ABBV
--
ABBV:CA
--